Pharma Business review is using cookies

ContinueLearn More
Close
August 16, 2018

Pfizer, BioNTech to develop mRNA-based vaccines for influenza

Biotechnology firm BioNTech has collaborated with Pfizer for the development of mRNA-based vaccines to prevent influenza (flu).

Continue
Image: BioNTech and Pfizer will develop mRNA-based vaccines to prevent influenza. Photo: courtesy of BioNTech AG.
August 15, 2018

Haplogen, Bayer enter into drug discovery and development collaboration

Image: Bayer to collaborate with Haplogen to develop new drugs for pulmonary diseases. Photo: courtesy of Bayer.
August 14, 2018

Izana begins phase II proof-of-concept study of spinal arthritis drug

Image: Izana Bioscience has started phase II proof-of-concept study of spinal arthritis drug. Photo: courtesy of rajcreationzs / FreeDigitalPhotos.net.

Contracts

July 3, 2018

Abzena signs manufacturing and bioconjugation deal with Telix

Ionis licenses to Akcea global rights to inotersen in $1.7bn deal

Recursion Pharmaceuticals uses Splunk machine learning to treat genetic diseases

Summit Therapeutics awarded BARDA contract to develop Ridinilazole for CDI

Deals

Deals August 13, 2018

Aralez Pharmaceuticals agrees to sell main operating businesses

Pharmaceutical Business Review

OvaScience, Millendo Therapeutics agree to merge

LEO Pharma to buy Bayer’s prescription dermatology brands

Leap Therapeutics to evaluate TRX518/avelumab combo for advanced solid tumors

Popular

  1. UK’s MHRA grants early access to Alnylam’s patisiran
  2. EMA grants orphan designation to selumetinib to treat neurofibromatosis type 1
  3. Summit’s Ridinilazole preserves gut microbiome of patients with C. difficile infection
  4. Karuna raises $42m to advance KarXT into phase 2 study
  5. Celtaxsys’ CF drug acebilustat reduces pulmonary exacerbations in phase 2 trial

Videos

Suppliers

Spotlight

Pharmaceutical Business Review
Oxford BioMedica forms three-way partnership for cystic fibrosis treatment
Pharmaceutical Business Review
Spark Therapeutics reports mixed results from hemophilia gene therapy trial
Pharmaceutical Business Review
AstraZeneca to pay $110m to settle Texas whistleblower drug lawsuits